

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
Details : Difamilast is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 22, 2025
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difamilast is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2025
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 28, 2022
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 14, 2022
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difamilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difamilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 07, 2022
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Launch in Japan of Moizerto® Ointment, a Treatment for Atopic Dermatitis
Details : Moizerto (Difamilast) Ointment is a non-steroidal, topical phosphodiesterase type-4 inhibitor (commonly called a PDE4 inhibitor), improve the symptoms of atopic dermatitis.
Product Name : Moizerto
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
Details : OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis
Details : Moizerto Ointment (difamilast), in 1% and 0.3% formulations, is a non-steroidal topical phosphodiesterase type 4 inhibitor (PDE4 inhibitor). Moizerto Ointment was discovered by Otsuka in Tokushima Research Institute and is the first topical PDE4 inhibito...
Product Name : Moizerto
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2021
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Medimetriks Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difamilast is a topical atopic dermatitis drug candidate discovered by Otsuka that has phosphodiesterase 4 (PDE4) inhibitory activity.
Product Name : Moizerto
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Medimetriks Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
